TY  - JOUR
AU  - Codina, Pau
AU  - Domingo, Mar
AU  - Barceló, Elena
AU  - Gastelurrutia, Paloma
AU  - Casquete, Daniel
AU  - Vila, Joan
AU  - Abdul-Jawad Altisent, Omar
AU  - Spitaleri, Giosafat
AU  - Cediel, Germán
AU  - Santiago-Vacas, Evelyn
AU  - Zamora, Elisabet
AU  - Ruiz-Cueto, María
AU  - Santesmases, Javier
AU  - de la Espriella, Rafael
AU  - Pascual-Figal, Domingo A
AU  - Nuñez, Julio
AU  - Lupón, Josep
AU  - Bayes-Genis, Antoni
PY  - 2022
DO  - 10.1002/ehf2.13952
UR  - http://hdl.handle.net/20.500.12105/15733
AB  - Prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH). The aim of the...
LA  - eng
PB  - Wiley
KW  - Heart Failure
KW  - Hypertension, Pulmonary
KW  - Aminobutyrates
KW  - Arterial Pressure
KW  - Biphenyl Compounds
KW  - Humans
KW  - Neprilysin
KW  - Quality of Life
KW  - Sodium Potassium Chloride Symporter Inhibitors
KW  - Stroke Volume
KW  - Tetrazoles
KW  - Valsartan
TI  - Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
TY  - journal article
ER  -